^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Factor XI inhibitor

    Associations

    News

    Trials
    1m
    ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (clinicaltrials.gov)
    P2, N=1200, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (clinicaltrials.gov)
    P3, N=2000, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    aspirin
    2ms
    To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Suzhou Alphamab Co., Ltd.
    New P1/2 trial
    3ms
    To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension (clinicaltrials.gov)
    P1, N=60, Recruiting, Suzhou Alphamab Co., Ltd.
    New P1 trial
    3ms
    Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (clinicaltrials.gov)
    P2, N=241, Active, not recruiting, Suzhou Alphamab Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    enoxaparin sodium
    3ms
    ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation (clinicaltrials.gov)
    P2, N=1200, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial
    3ms
    AZALEA-TIMI 71: Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation (clinicaltrials.gov)
    P2, N=1287, Active, not recruiting, Anthos Therapeutics, Inc. | Trial completion date: Dec 2025 --> Dec 2028
    Trial completion date
    4ms
    ASTER: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (clinicaltrials.gov)
    P3, N=1150, Active, not recruiting, Anthos Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=1655 --> 1150
    Enrollment closed • Enrollment change
    4ms
    A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (clinicaltrials.gov)
    P2, N=450, Not yet recruiting, Sirius Therapeutics Co., Ltd.
    New P2 trial
    |
    enoxaparin sodium
    5ms
    ROXI-APEX: REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults (clinicaltrials.gov)
    P3, N=2000, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=224, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    aspirin
    6ms
    Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=224, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Aug 2025 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    aspirin